These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Tuberculosis control in resource-poor countries: alternative approaches in the era of HIV. De Cock KM; Wilkinson D Lancet; 1995 Sep; 346(8976):675-7. PubMed ID: 7658822 [TBL] [Abstract][Full Text] [Related]
47. Stevens-Johnson syndrome during anti-tuberculosis chemotherapy in HIV-seropositive patients: report on six cases. Wirima JJ; Harries AD East Afr Med J; 1991 Jan; 68(1):64-6. PubMed ID: 2060484 [TBL] [Abstract][Full Text] [Related]
48. Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa. Marseille E; Kahn JG; Mmiro F; Guay L; Musoke P; Fowler MG; Jackson JB Lancet; 1999 Sep; 354(9181):803-9. PubMed ID: 10485721 [TBL] [Abstract][Full Text] [Related]
49. The new tuberculosis. De Cock K Afr Health; 1994 Mar; 16(3):8-10. PubMed ID: 12318774 [TBL] [Abstract][Full Text] [Related]
50. Priorities for HIV testing in developing countries? Colebunders R; Ndumbe P Lancet; 1993 Sep; 342(8871):601-2. PubMed ID: 8102727 [TBL] [Abstract][Full Text] [Related]
51. Rapid and simple screening and supplemental testing for HIV-1 and HIV-2 infections in west Africa. Brattegaard K; Kouadio J; Adom ML; Doorly R; George JR; De Cock KM AIDS; 1993 Jun; 7(6):883-5. PubMed ID: 8395857 [TBL] [Abstract][Full Text] [Related]
52. [Skin toxicity of thiacetazone (TB1) at a hospital service in Dakar]. Dieng MT; Ndiaye B; Camara C Dakar Med; 2001; 46(1):1-3. PubMed ID: 15773145 [TBL] [Abstract][Full Text] [Related]
54. Cost of managing severe cutaneous adverse drug reactions to first-line tuberculosis therapy in South Africa. Knight LK; Lehloenya RJ; Sinanovic E; Pooran A Trop Med Int Health; 2019 Aug; 24(8):994-1002. PubMed ID: 31173430 [TBL] [Abstract][Full Text] [Related]
55. Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counselling and testing centre. Aisu T; Raviglione MC; van Praag E; Eriki P; Narain JP; Barugahare L; Tembo G; McFarland D; Engwau FA AIDS; 1995 Mar; 9(3):267-73. PubMed ID: 7755915 [TBL] [Abstract][Full Text] [Related]
56. Tuberculosis in sub-Saharan Africa: a regional assessment of the impact of the human immunodeficiency virus and National Tuberculosis Control Program quality. Cantwell MF; Binkin NJ Tuber Lung Dis; 1996 Jun; 77(3):220-5. PubMed ID: 8758104 [TBL] [Abstract][Full Text] [Related]
57. Tuberculin sensitivity and HIV-1 status of patients attending a sexually transmitted diseases clinic in Lusaka, Zambia: a cross-sectional study. Duncan LE; Elliott AM; Hayes RJ; Hira SK; Tembo G; Mumba GT; Ebrahim SH; Quigley M; Pobee JO; McAdam KP Trans R Soc Trop Med Hyg; 1995; 89(1):37-40. PubMed ID: 7747304 [TBL] [Abstract][Full Text] [Related]
58. Contemporary treatment of tuberculosis in HIV prevalent countries in sub-Saharan Africa. Nuwaha F East Afr Med J; 1998 Jun; 75(6):358-63. PubMed ID: 9803621 [TBL] [Abstract][Full Text] [Related]
59. Outcomes of reintroducing anti-tuberculosis drugs following cutaneous adverse drug reactions. Lehloenya RJ; Todd G; Badri M; Dheda K Int J Tuberc Lung Dis; 2011 Dec; 15(12):1649-57. PubMed ID: 22118173 [TBL] [Abstract][Full Text] [Related]